Proteomics International Laboratories Limited (PIQ.AX)
AUD 0.45
(-4.26%)
AUD 0.45
(-4.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 892.14 Thousand AUD | -90.65% |
| 2023 | 9.54 Million AUD | 13.55% |
| 2022 | 8.4 Million AUD | 44.5% |
| 2021 | 5.81 Million AUD | 22.83% |
| 2020 | 4.73 Million AUD | 4.38% |
| 2019 | 4.53 Million AUD | 28.77% |
| 2018 | 3.52 Million AUD | 154.52% |
| 2017 | -6.46 Million AUD | -337.18% |
| 2016 | 2.72 Million AUD | 83.6% |
| 2015 | 1.48 Million AUD | 56.49% |
| 2014 | 948.55 Thousand AUD | -35.4% |
| 2013 | 1.46 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 4.67 Million AUD | 0.0% |
| 2024 Q2 | 785.03 Thousand AUD | 0.0% |
| 2024 FY | 1.5 Million AUD | -84.26% |
| 2023 Q1 | 1.83 Million AUD | 197.33% |
| 2023 Q2 | 519.13 Thousand AUD | -71.65% |
| 2023 FY | 9.54 Million AUD | 13.55% |
| 2023 Q3 | 1.77 Million AUD | 241.39% |
| 2023 Q4 | 450.14 Thousand AUD | -74.6% |
| 2022 Q2 | 922.84 Thousand AUD | 0.0% |
| 2022 Q4 | 615.79 Thousand AUD | -62.73% |
| 2022 FY | 8.4 Million AUD | 44.5% |
| 2022 Q3 | 1.65 Million AUD | 79.02% |
| 2021 FY | 5.81 Million AUD | 22.83% |
| 2021 Q1 | 513.24 Thousand AUD | -38.78% |
| 2021 Q2 | 915.73 Thousand AUD | 78.42% |
| 2021 Q3 | 1.2 Million AUD | 31.76% |
| 2021 Q4 | 989.69 Thousand AUD | -17.98% |
| 2020 FY | 4.73 Million AUD | 4.38% |
| 2020 Q4 | 838.35 Thousand AUD | 63.34% |
| 2020 Q3 | 513.24 Thousand AUD | -9.88% |
| 2020 Q2 | 569.51 Thousand AUD | 0.0% |
| 2019 Q1 | 1.29 Million AUD | -9.52% |
| 2019 Q4 | 541.31 Thousand AUD | 10.09% |
| 2019 Q3 | 491.7 Thousand AUD | -80.98% |
| 2019 Q2 | 2.58 Million AUD | 100.0% |
| 2019 FY | 4.53 Million AUD | 28.77% |
| 2018 Q2 | 1.42 Million AUD | 100.0% |
| 2018 Q1 | 712.59 Thousand AUD | -25.66% |
| 2018 Q4 | 1.42 Million AUD | 277.13% |
| 2018 Q3 | 378.9 Thousand AUD | -73.41% |
| 2018 FY | 3.52 Million AUD | 154.52% |
| 2017 Q3 | -2.03 Million AUD | -273.64% |
| 2017 Q2 | 1.17 Million AUD | 100.0% |
| 2017 Q4 | 958.53 Thousand AUD | 147.04% |
| 2017 FY | -6.46 Million AUD | -337.18% |
| 2017 Q1 | 586.78 Thousand AUD | -50.01% |
| 2016 Q2 | 1.15 Million AUD | 834.07% |
| 2016 FY | 2.72 Million AUD | 83.6% |
| 2016 Q3 | 219.2 Thousand AUD | -81.06% |
| 2016 Q1 | 123.92 Thousand AUD | -90.29% |
| 2016 Q4 | 1.17 Million AUD | 435.45% |
| 2015 FY | 1.48 Million AUD | 56.49% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q3 | 123.92 Thousand AUD | -72.31% |
| 2015 Q4 | 1.27 Million AUD | 929.42% |
| 2015 Q2 | 447.46 Thousand AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 FY | 948.55 Thousand AUD | -35.4% |
| 2013 FY | 1.46 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | 86.821% |
| Acrux Limited | 8.55 Million AUD | 89.566% |
| Race Oncology Limited | 14.77 Million AUD | 93.96% |
| Biome Australia Limited | 7.91 Million AUD | 88.723% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -48.241% |
| BTC Health Limited | -1.03 Million AUD | 185.872% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 95.487% |
| CSL Limited | 7.56 Billion AUD | 99.988% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 98.416% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 97.149% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 97.746% |
| Hexima Limited | 1 Million AUD | 11.56% |
| Immutep Limited | 42.87 Million AUD | 97.919% |
| Memphasys Limited | 3.67 Million AUD | 75.746% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 97.271% |
| Noxopharm Limited | 7 Million AUD | 87.255% |
| Prescient Therapeutics Limited | 10.89 Million AUD | 91.814% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -198.148% |
| Starpharma Holdings Limited | 22.81 Million AUD | 96.09% |
| Tissue Repair Ltd | 6.66 Million AUD | 86.618% |
| Biotron Limited | 5.11 Million AUD | 82.544% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 96.189% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -25.616% |
| Bio-Gene Technology Limited | 2.76 Million AUD | 67.688% |
| Zelira Therapeutics Limited | 5.94 Million AUD | 85.002% |
| Patrys Limited | 4.93 Million AUD | 81.916% |
| Orthocell Limited | 15.36 Million AUD | 94.195% |
| Imugene Limited | 135.09 Million AUD | 99.34% |
| PYC Therapeutics Limited | 60.91 Million AUD | 98.535% |
| Cynata Therapeutics Limited | 11.12 Million AUD | 91.98% |
| Arovella Therapeutics Limited | 10.78 Million AUD | 91.728% |
| Nanollose Limited | 12.5 Thousand AUD | -7036.573% |
| Invex Therapeutics Ltd | 3.34 Million AUD | 73.336% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | 54.603% |
| Amplia Therapeutics Limited | 8.43 Million AUD | 89.424% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | 78.374% |
| Nyrada Inc. | 4.55 Million AUD | 80.415% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 99.669% |
| Dimerix Limited | 25.64 Million AUD | 96.521% |
| PharmAust Limited | 6.65 Million AUD | 86.598% |
| AnteoTech Limited | 12.18 Million AUD | 92.68% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 98.63% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 95.886% |
| Avecho Biotechnology Limited | 4.54 Million AUD | 80.373% |
| Actinogen Medical Limited | 22.77 Million AUD | 96.082% |
| Immuron Limited | 9.13 Million AUD | 90.237% |
| Argenica Therapeutics Limited | 8.26 Million AUD | 89.211% |